biostudies-literatureGong Z1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan UniversityPostdoctor Research Fund of West China Hospital, Sichuan University71https://www.ebi.ac.uk/biostudies/studies/S-EPMC11817876biostudies-literatureUnknown25(1)<h4>Background</h4>Observational studies have identified a possible connection between lipid-lowering medications and respiratory illnesses. However, it remains unclear whether lipid-lowering drugs is causative for respiratory diseases, and we aimed to answer this question.<h4>Methods</h4>We performed Mendelian randomization (MR) analyses by integrating data from genome-wide association studies (GWAS). Three statistical approaches were employed for MR analysis: inverse variance weighting (IVW), MR-Egger, and weighted median. The purpose was to evaluate the causal relationships between 10 drug targets that lower lipid levels and the likelihood of developing 7 respiratory diseases. Additional sensitivity analyses were conducted to ensure the robustness and validity of the results.<h4>ResultsBMC pulmonary medicineLipid-lowering drug targets associated with risk of respiratory disease: a Mendelian randomization study.PMC118178762023HXBH045 to Xiaohu HaoZYJC21002 to Lunxu LiuKu YLiu LHao XWu DZou CGong ZQiu LfalseLipid-lowering drug targets associated with risk of respiratory disease: a Mendelian randomization study.<h4>Background</h4>Observational studies have identified a possible connection between lipid-lowering medications and respiratory illnesses. However, it remains unclear whether lipid-lowering drugs is causative for respiratory diseases, and we aimed to answer this question.<h4>Methods</h4>We performed Mendelian randomization (MR) analyses by integrating data from genome-wide association studies (GWAS). Three statistical approaches were employed for MR analysis: inverse variance weighting (IVW), MR-Egger, and weighted median. The purpose was to evaluate the causal relationships between 10 drug targets that lower lipid levels and the likelihood of developing 7 respiratory diseases. Additional sensitivity analyses were conducted to ensure the robustness and validity of the results.<h4>Results2025-01-01T00:00:00Z2025 Feb2025-04-04T02:57:19.856Z2025-04-04T02:57:19.856ZS-EPMC118178763993477310.1186/s12890-025-03527-x